IN THE CLAIMS

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Claims 1-24 (canceled)

25. (previously presented) A composition comprising a first ester prodrug of florfenicol, a second ester prodrug of florfenicol, and a pharmaceutically acceptable carrier, wherein the composition is formulated as a composition for administration to a mammal by injection.

26. (previously presented) The composition of claim 25, wherein the concentration of the prodrugs of florfenicol in the composition is at least about 200 mg/mL.

27. (previously presented) The composition of claim 25, wherein at least one of the ester prodrugs of florfenicol is an ester formed between florfenicol and a carboxylic acid.

28. (previously presented) The composition of claim 25, wherein both the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are an ester formed between florfenicol and a carboxylic acid.

29. (previously presented) The composition of claim 25, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.

30. (previously presented) The composition of claim 29, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, florfenicol phthalate.

31. (previously presented) The composition of claim 25, wherein the composition forms a drug depot when injected into a mammal.

32. (previously presented) The composition of claim 25, wherein the pharmaceutically acceptable carrier is selected from the group consisting of N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof.

33. (previously presented) The composition of claim 32, wherein the pharmaceutically acceptable carrier is selected from the group consisting of propylene glycol, glycerol formal, and combinations thereof.

34. (previously presented) A composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof, wherein the composition is formulated as a composition for administration to a mammal by injection.

35. (previously presented) The composition of claim 34, wherein the solvent is selected from propylene glycol, glycerol formal, and combinations thereof.

36. (previously presented) The composition of claim 35, wherein the pharmaceutically acceptable carrier is a combination of propylene glycol and glycerol formal.

37. (previously presented) The composition of claim 34, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL.

38. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 25.

39. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 26.

40. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 27.

41. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 28.

42. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 29.

43. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 30.

44. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 32.

45. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 34.

46. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 35.

47. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 36.

48. (previously presented) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 37.

49. (New) A composition comprising (i) a first ester prodrug of florfenicol having a first release rate, (ii) a second ester prodrug of florfenicol have a second release rate, and (iii) a pharmaceutically acceptable carrier, wherein the composition is formulated for administration to a mammal by injection, the composition forms a drug depot when injected into the mammal, and the first release rate is different from the second release rate.